MedTrace Logo

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

NCT01532102 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-05-30

No results posted yet for this study

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).

Conditions

  • Anogenital Warts
  • Condylomata Acuminata
  • Human Papillomavirus Infection

Interventions

DRUG

AP611074

DRUG

Placebo

Placebo gel manufactured to appear identical to AP611074 5% gel

Sponsors & Collaborators

  • Anaconda Pharma

    lead INDUSTRY

Principal Investigators

  • Olivier Chosidow, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-28
Primary Completion
2013-05-06
Completion
2013-05-06

Countries

  • Argentina
  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01532102 on ClinicalTrials.gov